However, with larger starting tumor volumes (~190 mm3), only partial regressions are observed which allows for the evaluation of enhanced anti-tumor activity in an anti-TIGIT and anti-PD-1 combination approach. The gene discussed is PDCD1; the disease is neoplasm.